Arrowhead Pharmaceuticals (ARWR) Financials

Arrowhead Pharmaceuticals’ latest quarter shows a mixed picture: improving revenue and a strong cash position, but ongoing operating losses and heavy spending remain the big story. In Q2 2026, revenue came in at $73.7 million versus $264.0 million in Q1 2026, and the company swung back to a net loss of $137.6 million after posting a profit in the prior quarter. That kind of volatility is common for biotech companies, but investors will still want to see more consistent commercialization or partnership-driven revenue.

One of the biggest positives is the balance sheet. At March 31, 2026, Arrowhead held $1.78 billion in cash, cash equivalents, and short-term investments, compared with $916.6 million at the end of Q1 2026 and $904.0 million a year earlier. That gives the company a substantial cushion to fund R&D and operations. Total current assets were $1.84 billion, while total liabilities were $1.67 billion, leaving shareholders’ equity at $614.0 million.

Operating losses, however, are still substantial. In Q2 2026, operating expenses totaled $215.0 million, with R&D at $173.3 million and SG&A at $41.7 million. The company reported an operating loss of $141.3 million. Even though other income partially helped, the quarter still ended with a net loss and basic EPS of $(0.93).

Cash flow also showed that Arrowhead is still consuming capital, though the company remains funded well for now. Operating cash flow was positive at $84.4 million in Q2 2026, helped by large changes in operating assets and liabilities. But investing activity was a major outflow due to $924.6 million of investment purchases, and financing added $795.7 million, largely from common equity issuance. Net cash declined by $14.1 million during the quarter.

Looking at the last several years, a few trends stand out:

• Cash and short-term investments remain very strong, giving Arrowhead a deep liquidity reserve.
• Revenue in Q1 2026 was $264.0 million, a sharp improvement from prior periods and a sign that the business can generate meaningful non-dilutive income when deals or milestones hit.
• The company produced positive operating cash flow in both Q1 and Q2 2026.
• Total current assets exceeded total liabilities in Q2 2026, which is a healthy near-term liquidity position.
• Revenue has been highly uneven from quarter to quarter, reflecting the lumpy nature of biotech partnerships and milestone payments.
• R&D spending remains elevated, which is expected for a development-stage biotech but also keeps profitability out of reach for now.
• Debt remains meaningful, with $40.0 million of short-term debt and $841.6 million of long-term debt in Q2 2026.
• Q2 2026 produced a $137.6 million net loss, showing the company is still far from consistent bottom-line profitability.
• Operating expenses continue to run well above quarterly revenue in most periods.
• Share count has risen over time, including common equity issuance in recent quarters, which can dilute existing shareholders.

Bottom line: Arrowhead looks financially flexible thanks to a large cash/investment position, but the company is still operating like a cash-burning biotech with volatile revenue and persistent losses. For retail investors, the key question is whether upcoming partnership income, product progress, or clinical wins can turn the current financial strength into a more durable earnings story.